Close

Unusual 11 Midday Movers 02/02: (MTSN) (GMCR) (CEDC) Higher; (MERU) (CMED) (SHOR) Lower

February 2, 2012 2:31 PM EST
Mattson Technology, Inc. (NASDAQ: MTSN) 23% HIGHER; reported Q4 EPS of ($0.07), $0.04 better than the analyst estimate of ($0.11). Revenue for the quarter came in at $41.7 million versus the consensus estimate of $36.25 million. The company was also upgraded today by Craig-Hallum to a Buy rating.

Green Mountain Coffee Roasters (NASDAQ: GMCR) 21.9% HIGHER; reported Q1 EPS of $0.60, $0.24 better than the analyst estimate of $0.36. Revenue for the quarter came in at $1.16 billion versus the consensus estimate of $1.06 billion.

Central European Distribution Corp. (Nasdaq: CEDC) 19.5% HIGHER; shares are higher following a proposal by Russian Standard for a strategic investment in CEDC. Click here for the full report.

Meru Networks, Inc. (NASDAQ: MERU) 20% LOWER; reported Q4 EPS of ($0.30), $0.01 better than the analyst estimate of ($0.31). Revenue for the quarter came in at $23.3 million versus the consensus estimate of $24.12 million.

China Medical Technologies (Nasdaq: CMED) 19.8% LOWER; Fitch withdrew its rating on the company.

Compugen Ltd. (Nasdaq: CGEN) 19.3% HIGHER; announced today results demonstrating the therapeutic potential of CGEN-15001T as a drug target for treatment of multiple cancers by means of monoclonal antibody (“mAb”) therapy. These results indicate that CGEN-15001T is expressed on numerous types of cancer, such as carcinomas, sarcomas, melanoma and hematological cancers as well as on immune cells. These findings, together with previous results supporting its active immunomodulatory effect, strongly support CGEN-15001T’s potential as a powerful drug target for treatment of various solid and hematological cancers, an area of great interest to the pharmaceutical industry.

Zynga (Nasdaq: ZNGA) 18.6% HIGHER; shares are trading higher today after Facebook confirmed they receive 12 percent of their total revenues from Zynga games. Some investors believe Facebook may attempt to acquire the online gaming company.

Shoretel, Inc. (NASDAQ: SHOR) 18.5% LOWER; reported Q2 EPS of $0.03, $0.04 better than the analyst estimate of ($0.01). Revenue for the quarter came in at $58 million versus the consensus estimate of $55.63 million. The stock was downgraded at Craig-Hallum.

Brinks Co. (NYSE: BCO) 18.4% LOWER; reported Q4 non-GAAP EPS of $0.56, $0.07 worse than the analyst estimate of $0.63. Revenue for the quarter came in at $997 billion versus the consensus estimate of $1.05 billion.

Dice Holdings, Inc. (NYSE: DHX) 18% LOWER; reported Q4 EPS of $0.15, in-line with the analyst estimate of $0.15. Revenue for the quarter came in at $47.4 million versus the consensus estimate of $47.33 million. Sees Q1 2012 revenue of $46 million, versus the consensus of $46.83 million. Sees FY2012 revenue of $197 million, versus the consensus of $201.09 million.

Discovery Laboratories, Inc. (NASDAQ: DSCO) 17.5% HIGHER; today announced AFECTAIR® is now registered with the FDA and is cleared to be marketed in the United States. AFECTAIR is a proprietary patient interface technology that simplifies delivery of aerosolized medications to patients requiring ventilator support.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Special Reports